Therapeutic liabilities of in vivo viral vector tropism: adeno-associated virus vectors, NMDAR1 antisense, and focal seizure sensitivity - Wikidata - awgldk - TriplyDB

Therapeutic liabilities of in vivo viral vector tropism: adeno-associated virus vectors, NMDAR1 antisense, and focal seizure sensitivity

Therapeutic liabilities of in vivo viral vector tropism: adeno-associated virus vectors, NMDAR1 antisense, and focal seizure sensitivity

http://www.wikidata.org/entity/Q35542643

about

Current prospects and challenges for epilepsy gene therapy Changing channels in pain and epilepsy: Exploiting ion channel gene therapy for disorders of neuronal hyperexcitability Knockdown and overexpression of NR1 modulates NMDA receptor function.Adenosine kinase, glutamine synthetase and EAAT2 as gene therapy targets for temporal lobe epilepsy.Engineered HSV vector achieves safe long-term transgene expression in the central nervous system.Gene therapy in epilepsy.Recent advancements in stem cell and gene therapies for neurological disorders and intractable epilepsy.Inhibitory RNA in epilepsy: research tools and therapeutic perspectives Gene therapy in epilepsy-is it time for clinical trials?An adeno-associated virus-based intracellular sensor of pathological nuclear factor-κB activation for disease-inducible gene transfer.Adenosine kinase as a target for therapeutic antisense strategies in epilepsy.The promise of gene therapy for the treatment of epilepsy.AAV vectors for RNA-based modulation of gene expression.Neuropeptide Y overexpression using recombinant adeno-associated viral vectors.Adeno-associated virus vector-mediated expression and constitutive secretion of galanin suppresses limbic seizure activity.A next step in adeno-associated virus-mediated gene therapy for neurological diseases: regulation and targeting.Progress in gene therapy for neurological disorders.Adeno-Associated Virus-Based Gene Therapy for CNS Diseases.RANGE: Gene Transfer of Reversibly Controlled Polycistronic Genes.Preferential labeling of inhibitory and excitatory cortical neurons by endogenous tropism of adeno-associated virus and lentivirus vectors.On demand up-regulation of therapeutic genes in the brain: fiction or reality?Attenuation of seizures and neuronal death by adeno-associated virus vector galanin expression and secretion.

P2860

Q27002627-5036E450-FBBB-498E-83E0-93AD2B1396AB Q28081164-746BEE38-C82A-47BE-A863-AD07B394E0B8 Q30451702-2DABC309-0917-4208-B2BB-D428CD317E1E Q30605561-A4F4A1F4-2694-4976-A1C4-FC35F01A7C72 Q33685490-A2396BDB-E27E-428E-8412-52BAE314F472 Q33960096-328DD811-7286-4B51-95B8-2165C71B2D72 Q34098055-08DB433C-783C-4375-9721-8F7CF4970EE6 Q34126428-F4533078-02CD-416E-B7F3-47B630829744 Q34410588-57AFDAC1-B6AB-4CA3-B889-1F5E8C641760 Q34542364-C3261890-F3C5-4C5E-BF23-8685D35943E5 Q34788009-446A9D5C-CC08-4B43-BC5F-D4B97887C3D6 Q37021317-6099897D-DCFE-4473-AD3E-E29798732896 Q37140645-20930A93-7922-41E9-9B22-DE9F7D07EB74 Q37426975-DB8268C1-835E-4A8E-9036-16038E3FE317 Q37426979-C0256207-2644-45AC-ACAC-A529FAFA4687 Q38075068-1A0821B3-B4AE-4AF4-8FE8-F4E2D8AD3973 Q38100997-4CE9A496-5B93-4FC2-AA90-E996E3836B45 Q38856794-64CB1295-0849-4C18-8D86-2C68C3E9E7E5 Q40596482-18C87BA1-5F83-4C72-91B8-92619F2A90C4 Q41841802-351EF072-EA01-43C6-8CFB-B4CF06159A8F Q42008294-7A100855-9AE5-4189-9B47-3CE533BFA178 Q44511379-E3E8BD9E-D1AA-40F7-A60C-F4B34D9904C6

P2860

Therapeutic liabilities of in vivo viral vector tropism: adeno-associated virus vectors, NMDAR1 antisense, and focal seizure sensitivity

http://www.wikidata.org/entity/Q35542643

description

2002 nî lūn-bûn

@nan

2002 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Therapeutic liabilities of in ...... and focal seizure sensitivity

@ast

Therapeutic liabilities of in ...... and focal seizure sensitivity

@en

type

label

Therapeutic liabilities of in ...... and focal seizure sensitivity

@ast

Therapeutic liabilities of in ...... and focal seizure sensitivity

@en

prefLabel

Therapeutic liabilities of in ...... and focal seizure sensitivity

@ast

Therapeutic liabilities of in ...... and focal seizure sensitivity

@en

P1433

Q35542643-82005C59-D5E4-4B4C-9B8D-42A638591335

P1476

Q35542643-9AD8C745-E3BE-48A9-A8F8-7D95CB7D6633

P2093

Q35542643-0EF3D879-1C1E-4F22-8D2E-2C8833FCDCF9

Q35542643-145AD05B-6DED-4A5D-A3E5-AC84EACBBCBE

Q35542643-256ADBA8-BB64-47A2-BB2B-5CEC39706A8A

Q35542643-46C1ED19-361E-44CE-838E-F270C6C80167

Q35542643-55119883-B853-4855-B5A3-63772290AC85

Q35542643-56AAD810-76A9-432B-B94F-96709DF6A8AE

Q35542643-94A9F748-428A-415A-B51A-92E4B12ECFF4

P2860

Q35542643-0416A096-16DA-49EB-A2B1-691309708FBB

Q35542643-10F09373-4202-4747-8344-9897A166DE29

Q35542643-1975F582-5889-4CC3-A08F-35F49879C2B1

Q35542643-25E1081F-057B-44C9-86C3-3F398C5594BB

Q35542643-2961731F-5F62-444A-96A7-965E82358721

Q35542643-31913158-80B4-4549-B9DF-7DCEC50B5A39

Q35542643-381D81C1-A348-4B0D-B371-BE99A222000D

Q35542643-44E35265-3266-400A-BF16-E1C6C8FA6C9B

Q35542643-496EA07D-C74F-4D36-B798-BD33A3B1470A

Q35542643-4C4A7566-4020-4CA4-9588-BF52CBA4740E

P304

Q35542643-9CD4631A-720E-4BD7-87C0-9D372341C710

P31

Q35542643-AA667325-5E7F-42BD-B79F-E947CF80A456

P356

Q35542643-60742BBB-476B-4909-AABC-90FB4FF86A46

P433

Q35542643-E6CCDAB7-7CAF-46AB-AD48-14BC28F9E291

P478

Q35542643-A0727B12-F875-4DF2-A307-E9DD4F383B55

P577

Q35542643-E5B6C697-BCEF-4A22-A192-8EB244A90713

P5875

Q35542643-7812307D-254C-482D-9239-9D9F861A2B2E

P698

Q35542643-23340724-C531-49BF-B912-67207AF4EE0C

P921

Q35542643-82B0B198-7303-425B-A794-FB34E359E520

P932

Q35542643-F8CF2E2C-4692-4AFA-83BE-9A79617BDCB5

P356

P1433

Molecular Therapy

P1476

Therapeutic liabilities of in ...... and focal seizure sensitivity

@en

P2093

George Breese

http://www.w3.org/2001/XMLSchema#string

Hugh Criswell

http://www.w3.org/2001/XMLSchema#string

R Samulski

http://www.w3.org/2001/XMLSchema#string

Rebecca Haberman

http://www.w3.org/2001/XMLSchema#string

Stephen Snowdy

http://www.w3.org/2001/XMLSchema#string

Thomas McCown

http://www.w3.org/2001/XMLSchema#string

Zhen Ming

http://www.w3.org/2001/XMLSchema#string

P2860

Heteromeric NMDA receptors: molecular and functional distinction of subtypes

PIN: an associated protein inhibitor of neuronal nitric oxide synthase

Cloned glutamate receptors

Tufted cell dendrodendritic inhibition in the olfactory bulb is dependent on NMDA receptor activity.

Selective and rapid uptake of adeno-associated virus type 2 in brain.

Reduced MK801 binding in neocortical neurons after AAV-mediated transfections with NMDA-R1 antisense cDNA.

Effects of NMDA-R1 antisense oligodeoxynucleotide administration: behavioral and radioligand binding studies.

Novel transcriptional regulatory signals in the adeno-associated virus terminal repeat A/D junction element.

Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-L-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson's disease.

Glutamate, GABA and epilepsy.

P304

495-500

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1006/MTHE.2002.0701

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2002-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

278666539

http://www.w3.org/2001/XMLSchema#string

P698

12377191

http://www.w3.org/2001/XMLSchema#string

P921

vector-borne disease

P932

3213639

http://www.w3.org/2001/XMLSchema#string